Company Release no. 10/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 03 June 2019   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Investor News no. 03/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 31 May 2019 Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress Veloxis Pharmaceuticals (OMX: VELO) announced today that the Company’s

Company Release no. 09/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 07 May 2019   Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program     Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue

Company Release no. 08/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 06 May 2019   Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2019   Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim

Investor News no. 02/2019 To: NASDAQ Copenhagen A/S                                                   Copenhagen, Denmark, 1 May 2019   Veloxis to Host Conference Call Following Release of Interim Financial Report for the Period 1 January to 31 March 2019   Veloxis Pharmaceuticals A/S (NASDAQ:

Company Release no. 07/2019 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 04 April 2019 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and

Company Release no. 06/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 03 April 2019   Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2019   Summary: At Veloxis Pharmaceuticals A/S’ Annual General Meeting held earlier today,

Company Release no. 05/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 02 April 2019   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 04/2019 To: NASDAQ Copenhagen A/S                                                       Copenhagen, Denmark, 20 March 2019   Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been

Company Release no. 03/2019 To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 12 March 2019 Notice to Convene Annual General Meeting 2019 The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the annual

Company Release no. 02/2019 To: NASDAQ Copenhagen A/S                                                                     Copenhagen, Denmark, 27 February 2019   Veloxis Pharmaceuticals Releases Annual Report for 2018   Veloxis Pharmaceuticals A/S (OMX: VELO) today releases its Annual Report for

  Investor News no. 01/2019 To: NASDAQ Copenhagen A/S                                                   Copenhagen, Denmark, 26 February 2019 Veloxis to Host Conference Call Following Release of 2018 Annual Report As previously announced, Veloxis Pharmaceuticals A/S (NASDAQ: VELO) will release its

Company Release no. 01/2019 To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 03 January 2019   Mark Hensley Promoted to Chief Commercial Officer of Veloxis Pharmaceuticals   Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Mark